6:08 PM
 | 
Mar 08, 2010
 |  BC Extra  |  Clinical News

Recentin misses mCRC endpoint

AstraZeneca plc (LSE:AZN; NYSE:AZN) said top-line data showed that Recentin cediranib plus FOLFOX missed the primary endpoint of non-inferiority to Avastin bevacizumab plus...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >